Clinical Trial Update: Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating cisplatin plus gefitinib with re-irradiation in patients with recurrent head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Stanford University | Conditions: Head and Neck Cancer, Carcinoma, Squamous Cell | Phase 1 | Status: COMPLETED